{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:59:47Z","timestamp":1791284387027,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.juro.2016.02.3005","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T14:07:57Z","timestamp":1469542077000},"page":"14-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Immunotherapy for the Treatment of Urothelial Carcinoma"],"prefix":"10.1097","volume":"197","author":[{"given":"Nicholas M.","family":"Donin","sequence":"first","affiliation":[{"name":"Department of Urology, Institute of Urologic Oncology (NMD, SH, AD, AP, AB, KC), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Department of Medicine, Division of Hematology and Oncology (AD), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center (AD, AP, AB, KC), University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Lenis","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urologic Oncology (NMD, SH, AD, AP, AB, KC), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Department of Medicine, Division of Hematology and Oncology (AD), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center (AD, AP, AB, KC), University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Holden","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urologic Oncology (NMD, SH, AD, AP, AB, KC), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Department of Medicine, Division of Hematology and Oncology (AD), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center (AD, AP, AB, KC), University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urologic Oncology (NMD, SH, AD, AP, AB, KC), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Department of Medicine, Division of Hematology and Oncology (AD), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center (AD, AP, AB, KC), University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Pantuck","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urologic Oncology (NMD, SH, AD, AP, AB, KC), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Department of Medicine, Division of Hematology and Oncology (AD), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center (AD, AP, AB, KC), University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Belldegrun","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urologic Oncology (NMD, SH, AD, AP, AB, KC), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Department of Medicine, Division of Hematology and Oncology (AD), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center (AD, AP, AB, KC), University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Chamie","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urologic Oncology (NMD, SH, AD, AP, AB, KC), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Department of Medicine, Division of Hematology and Oncology (AD), David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center (AD, AP, AB, KC), University of California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2016.02.3005_bib1","first-page":"3","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893","volume":"262","author":"Coley","year":"1991","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.juro.2016.02.3005_bib2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.juro.2016.02.3005_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.juro.2016.02.3005_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.juro.2016.02.3005_bib6","series-title":"La Vaccination Pr\u00e9ventive contre la Tuberculose par le \u201cBCG\u201d","author":"Calmette","year":"1927"},{"issue":"suppl.","key":"10.1016\/j.juro.2016.02.3005_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/184291a0","article-title":"Effect of bacillus Calmette-Guerin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.juro.2016.02.3005_bib8","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/1097-0142(197511)36:5<1662::AID-CNCR2820360520>3.0.CO;2-6","article-title":"Successful transurethral intralesional BCG therapy of a bladder melanoma","volume":"36","author":"deKernion","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2016.02.3005_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib11","first-page":"CD001986","article-title":"Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer","volume":"4","author":"Shelley","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.juro.2016.02.3005_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Gu\u00e9rin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-5347(17)39547-2","article-title":"A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder","volume":"144","author":"Glashan","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1046\/j.1464-410X.2002.02734.x","article-title":"A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder","volume":"89","author":"Malmstr\u00f6m","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2016.02.3005_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0090-4295(97)00303-8","article-title":"Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): multicenter trial comparing bacille Calmette-Gu\u00e9rin and interferon-alpha","volume":"50","author":"Jimenez-Cruz","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.juro.2016.02.3005_bib19","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette-Gu\u00e9rin with or without interferon \u03b1-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib20","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O\u2019Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","article-title":"Bacillus Calmette-Gu\u00e9rin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity","volume":"21","author":"Lam","year":"2003","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2016.02.3005_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2016.02.3005_bib23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00345-007-0197-0","article-title":"p53 and retinoblastoma pathways in bladder cancer","volume":"25","author":"Mitra","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib25","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14760584.5.1.9","article-title":"Development of the PANVAC-VF vaccine for pancreatic cancer","volume":"5","author":"Petrulio","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.juro.2016.02.3005_bib27","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1158\/1078-0432.CCR-06-0527","article-title":"Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma","volume":"12","author":"Sharma","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2016.02.3005_bib28","first-page":"23","article-title":"Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide","volume":"7","author":"Nishiyama","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2016.02.3005_bib29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/CJI.0b013e3181891574","article-title":"Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF","volume":"31","author":"Sharma","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.juro.2016.02.3005_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11255-014-0866-z","article-title":"Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis","volume":"47","author":"Zhao","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.juro.2016.02.3005_bib31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"suppl.","key":"10.1016\/j.juro.2016.02.3005_bib32","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/jco.2015.33.15_suppl.4501","article-title":"A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC)","volume":"33","author":"Petrylak","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2016.02.3005_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2016.02.3005_bib34","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","article-title":"Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial","volume":"16","author":"Carthon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2016.02.3005_bib35","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm0902-1039c","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.juro.2016.02.3005_bib36","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2016.02.3005_bib37","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/jco.2016.34.2_suppl.355","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"suppl.","key":"10.1016\/j.juro.2016.02.3005_bib38","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/jco.2015.33.15_suppl.4502","article-title":"Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012","volume":"33","author":"Plimack","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2016.02.3005_bib39","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2016.02.3005_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.eururo.2009.09.026","article-title":"Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept","volume":"58","author":"Sherif","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.02.3005_bib41","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2016.02.3005_bib42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1200\/jco.2013.31.6_suppl.271","article-title":"Phase I\/II clinical trial of ALT-801, a T-cell receptor\/IL-2 fusion protein, plus gemcitabine and cisplatin in urothelial cancer","volume":"31","author":"Fishman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2016.02.3005_bib43","doi-asserted-by":"crossref","first-page":"e96705","DOI":"10.1371\/journal.pone.0096705","article-title":"Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion","volume":"9","author":"Gomes-Giacoia","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.juro.2016.02.3005_bib44","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.juro.2012.11.150","article-title":"Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer","volume":"189","author":"Falke","year":"2013","journal-title":"J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716309211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716309211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2016.02.3005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T04:35:37Z","timestamp":1651206937000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2016.02.3005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1016\/j.juro.2016.02.3005"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2016.02.3005","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for the Treatment of Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2016.02.3005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}